Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Athira Pharma, Inc. Director's Dealing 2023

May 22, 2023

35038_dirs_2023-05-22_a10c40ed-4ddc-4b19-9a72-a238476ddab3.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Athira Pharma, Inc. (ATHA)
CIK: 0001620463
Period of Report: 2023-05-18

Reporting Person: Gengos Andrew (See Below)

Holdings (Non-Derivative)

Security Shares Ownership
No securities are beneficially owned 0 Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
No securities are beneficially owned $0.00 Not applicable (0) Direct

Footnotes

F1: Not applicable